1 Clínica Puerta de Hierro and Department of Physiology, Universidad Autónoma de Madrid, 28035 Madrid, Spain; and 2 Amylin Pharmaceuticals Inc., San Diego, California 92121
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Amylin, a peptide hormone from
pancreatic -cells, is reported to inhibit insulin secretion in vitro
and in vivo and to inhibit nutrient-stimulated glucagon secretion in
vivo. However, it has been reported not to affect arginine-stimulated
glucagon secretion in vitro. To resolve if the latter resulted from
inactive peptide (a problem in the early literature), those experiments
were repeated here with well-characterized peptide and found to be
valid. In isolated perfused rat pancreas preparations, coperfusion with 1 nM amylin had no effect on arginine-, carbachol-, or vasoactive intestinal peptide-stimulated glucagon secretion. Amylin also had no
effect on glucagon output stimulated by decreasing glucose concentration from 11 to 3.2 mM or on glucagon suppression caused by
increasing glucose from 3.2 to 7 mM. Amylin at 100 nM had no effect in
isolated islets in which glucagon secretion was stimulated by exposure
to 10 mM arginine, even though glucagon secretion in the same
preparation was inhibited by somatostatin. In anesthetized rats, amylin
coinfusion had no effect on glucagon secretion stimulated by
insulin-induced hypoglycemia. To reconcile reports of glucagon inhibition with the absence of effect in the experiments just described, anesthetized rats coinfused with rat amylin or with saline
were exposed sequentially to intravenous L-arginine (during a euglycemic clamp) and then to hypoglycemia. Amylin inhibited arginine-induced, but not hypoglycemia-induced, glucagon secretion in
the same animal. In conclusion, we newly identify a selective glucagonostatic effect of amylin that appears to be extrinsic to the
isolated pancreas and may be centrally mediated.
rat pancreas; isolated islets; in vivo; amylin; glucagon
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
AMYLIN IS A
PANCREATIC -cell hormone cosecreted with insulin in response
to nutrients, including amino acids (19). Intravenous infusion of amylin into rats, at rates resulting in physiological plasma concentrations, inhibited arginine-stimulated glucagon secretion
by up to 70% (7). A similar glucagonostatic effect was
observed with the amylin analog pramlintide in rats (1, 5), and pramlintide administration inhibited the exaggerated postprandial glucagon surges observed in diabetic patients
(18).
In a previous study that appeared initially to contradict those results, pharmacological concentrations (500-750 nM) of rat amylin in the perfused rat pancreas had no effect on arginine-stimulated glucagon secretion (29). Because many preparations of amylin peptide commercially available at the time of that study had reduced or undetermined biological activity (15), we repeated those experiments using material established to be biologically active in isolated soleus muscle. We confirm in the present report that well-characterized rat amylin did not affect arginine-stimulated glucagon secretion in the isolated perfused pancreas or in isolated islets. This result caused us to further explore and identify those conditions where a suppression by amylin of glucagon secretion did or did not occur.
Amylin replacement therapy is proposed for use in diabetic patients treated with insulin, who are thereby susceptible to insulin-induced hypoglycemia. Glucagonostatic effects of amylin were therefore examined in the presence of low glucose concentrations in vivo and in vitro. Additionally, we examined its effects in vitro against peptidergic [vasoactive intestinal peptide (VIP)] and cholinergic (carbachol) glucagonotropic stimuli. Finally, to reconcile an absence of amylin effect under some circumstances with equally robust data showing an effect under other circumstances, we tested amylin's effects in rats in which both arginine and hypoglycemia were sequentially employed to stimulate glucagon secretion. The selective suppression of nutrient-stimulated glucagon secretion we identify here is discussed in relation to a proposed central (extrapancreatic) mode of action. Some of the data reported herein have been presented in preliminary communications (22, 30).
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Isolated perfused pancreas.
Male Wistar rats (200-225 g body wt) fed ad libitum from our
inbred colony were used as donors. Animals were maintained in accordance with the guidelines established by the European Union (86/609). After anesthesia of the rat with pentobarbital sodium (50 mg/kg ip), the pancreas was dissected and perfused in situ according to
the procedure of Leclercq-Meyer et al. (14) as adapted in
our laboratory (28). Effluent samples were collected from
the portal vein, without recycling, at 1-min intervals (flow rate, 2 ml/min) and frozen at 20°C until the time of assay. The perfusion
medium consisted of a Krebs-Henseleit buffer [in mM: 115 NaCl, 4.7 KCl, 2.6 CaCl2, 1.19 H2KPO4, 1.19 MgSO4 · 7H2O, and 24.9 HNaCO3 (gas phase 95% O2-5% CO2;
pH 7.4)] supplemented with 4% (wt/vol) dextran T-70 (Pharmacia LKB
Biotechnology, Uppsala, Sweden), 0.5% (wt/vol) Cohn fraction V bovine
albumin (Sigma Chemical, St. Louis, MO), and glucose (3.2, 5.5, or 11 mM; Sigma). Rat amylin (Amylin Pharmaceuticals, San Diego, CA) was
dissolved in 0.9% NaCl containing 0.1% bovine albumin (Cohn fraction
V). This solution (17.8 nM) was prepared daily, immediately before
experiments, and when added to the perfusate, the final concentration
was 1 nM amylin. After a 35-min equilibration period, baseline samples were collected for 5 min, and, at time 0, normal saline with
or without amylin was infused through a sidearm cannula. Glucagon secretion was stimulated by infusing 5 mM L-arginine
hydrochloride (Sigma), 1 nM VIP (Peninsula Laboratories
Europe), or 50 µM carbachol (Sigma) and by decreasing perfusate
glucose concentration from 11 to 3.2 mM. Integrity of the isolated
pancreas preparation was verified by measuring inhibition of glucagon
secretion while increasing perfusate glucose concentration from 3.2 to
7 mM. Glucagon was analyzed by RIA (4). Anti-glucagon
serum (Unger's O4A) was kindly donated by R. H. Unger (Health
Sciences Center, University of Texas, Dallas, TX). All samples for each
series of experiments were analyzed within the same assay.
Isolated islets.
As a further test of potential direct effects of amylin on pancreatic
islets, these were isolated from male Lewis rats (Harlan Sprague
Dawley, Indianapolis, IN) weighing between 150 and 200 g. Islets
of Langerhans were isolated from whole pancreas by use of a method of
collagenase digestion originally described by Kostianovsky et al.
(12) and modified by Lakey et al. (13).
Briefly, the pancreas was dissected free of fat, cleaned, and placed
into 5 ml of collagenase-P (1.8 mg/ml; Boehringer Mannheim) plus DNase (0.1 mg/ml), minced, and incubated at 37°C for 20 min. Digested pancreas was then shaken vigorously and washed in HEPES buffer, and
islets were separated on a Ficoll gradient. Selected islets were then
hand picked and cultured in RPMI/FCS (10%) for 3-4 days at 37°C
until experimentation. After being washed in RPMI media for 1 h
and then incubated in Hanks' BSS buffer containing 3 mM glucose for
1 h, triplicate groups of 15 islets were then incubated at 37°C
in fresh Hanks' buffer for a further hour of treatment, after which
media were collected and frozen at 70°C until assayed for glucagon.
Separate treatments consisted of addition of the following to buffer
medium: 3 mM D-glucose (control), 3 mM
D-glucose plus 10 mM L-arginine, 3 mM
D-glucose plus 10 mM L-arginine plus 100 nM
somatostatin, 3 mM D-glucose plus 10 mM
L-arginine plus 100 nM rat amylin.
Hypoglycemia-stimulated glucagon secretion in vivo.
Male Harlan Sprague-Dawley rats weighing ~350 g and fasted 18-20
h were halothane anesthetized and cannulated via the saphenous vein for
intravenous infusion/injection and via the femoral artery for sampling
analytes and for recording arterial pressure. Mean arterial pressure
(Spectramed P23XL transducer and Universal amplifier; Gould, Valley
View, OH), heart rate from an electrocardiogram (Biotach; Gould), and
colonic temperature were continuously recorded by computer interface
(Data Translation, Marlboro, MA). Heparinized (2 U/ml) saline was
infused via the arterial line at 3 ml/h from time (t) 60
min. At t =
30 min, rat amylin at 50 pmol · kg
1 · min
1 was added
or not added, and at t = 0 min, insulin was infused intravenously (or not) at 5 mU/min, with initiation of infusion being
accompanied by a 200-mU prime in some animals. There were thus five
treatment groups: 1) saline at t =
30 min,
saline at t = 0 min, n = 4, 2) amylin at t =
30 min, saline at
t = 0 min, n = 4; 3) saline
at t =
30 min, insulin at t = 0 min,
n = 4; 4) amylin at t =
30
min, insulin at t = 0 min, n = 6; and
5) amylin at t =
30 min, insulin plus
prime at t = 0 min, n = 4. The purpose
of the prime in group 5 was to compensate for an effect of
higher amylin doses to increase plasma glucose in nondiabetic rats
(36) and to thereby ensure that there was an
amylin-infused group that was as hypoglycemic or more hypoglycemic than
the insulin-only treatment group (group 3). Samples for
glucose and lactate were taken at
30,
15, and 0 min and every 5 min
thereafter until t = 120 min. Samples for glucagon were
taken at
30, 0, 10, 20, 30, 40, 50, 60, 75, 90, 105, and 120 min and
were measured by RIA (Linco Research, St. Charles, MO).
Effects of amylin on sequential arginine- and
hypoglycemia-stimulated glucagon secretion.
Animals were anesthetized and prepared as described above. Thirty
minutes after surgery, saline or rat amylin was infused continuously
intravenously at 50 pmol · kg1 · min
1
(n = 5-6) from t =
60 min until
the end of the experiment (t = 240 min). Insulin was
infused concurrently at 2 mU/min. At t = 0 min, 2 mmol
L-arginine were infused intravenously over 10 min. A
variable glucose infusion was used to clamp plasma glucose at 5.67 ± 0.06 mM until t = 120 min, whereupon glucose
infusion was ceased while still continuing insulin administration,
allowing plasma glucose to fall and remain low. To match the
hypoglycemic profile during this portion of the experiment,
amylin-treated rats received an additional 90 mU insulin bolus when
glucose infusion was stopped at t = 120 min to preempt
the rise in blood glucose after similar doses of amylin in nondiabetic
rats (36). Samples for glucose, amylin, and glucagon were
taken at the time points indicated in Fig. 5. Plasma glucose was
determined by immobilized oxidase chemistry on a YSI 2300 Stat Plus
(YSI, Yellow Springs, OH). Samples for glucagon were determined by RIA
(sensitivity 7 pM, interassay variability 7.9%, intra-assay
variability 10.9%; ICN Pharmaceuticals, Orangeburg, NY). Other
chemicals were obtained from Sigma. Plasma amylin concentrations were
determined using a specific two-site immunoenzymometric assay
(24).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Isolated perfused pancreas: secretagogues.
Glucagon responses to L-arginine, carbachol, and VIP, shown
in Fig. 1, A-C, indicate that
the perfused pancreas preparation was functioning. Addition of rat
amylin (1 nM) did not significantly modify the glucagon responses to
L-arginine (5 mM), carbachol (50 µM), or VIP (1 nM). In
these three experiments, amylin was also without effect on unstimulated
glucagon release, that is, during the 10-min perfusion period preceding
the infusion of secretagogues.
|
Isolated perfused pancreas: hypoglycemia.
As shown in Fig. 2A,
pancreases were initially perfused at a high glucose concentration (11 mM), and after 10 min, this concentration was abruptly lowered to 3.2 mM. This reduction of infusate glucose concentration was associated
with a progressive increase in glucagon output from 129 ± 31 pg/min at t = 5 min to 578 ± 99 pg/min at t = 30 min (P < 0.05). Restoration of
the initial 11 mM D-glucose concentration resulted in a
prompt decrease in glucagon release to basal values. Coinfusion of
amylin from t = 0 until t = 30 min had
no effect on the incremental glucagon response (4.8 ± 1 ng/25 min
in control experiments vs. 4.5 ± 1.3 ng/25 min in amylin
experiments; P = 0.8) and no apparent effect on the
glucagon secretory pattern.
|
Isolated islets.
Culturing islets in 10 mM arginine resulted in an increase in the rate
of glucagon secretion of 15.5 ± 4.3-fold over that observed in
the presence of 3 mM glucose (designated basal; P < 0.02; Fig. 3). Addition of 100 nM
somatostatin to islets cultured in 10 mM arginine reduced the 15.5-fold
stimulation of glucagon secretion by 55 ± 21% [not significant
(NS)]. In contrast, addition of 100 nM rat amylin to buffer containing
10 mM arginine did not reduce glucagon secretion (102 ± 46% of
islets treated with 10 mM arginine alone; NS vs. arginine stimulated;
Fig. 3).
|
Hypoglycemia-stimulated glucagon secretion in vivo.
In rats preinfused with saline only, insulin reduced plasma glucose
from 5.72 ± 0.22 to 2.11 ± 0.11 mM after 60 min of infusion (P < 0.001; Fig.
4A). In
rats preinfused with amylin, insulin reduced plasma glucose from
6.39 ± 0.17 to 2.39 ± 0.17 mM after 60 min
(P < 0.001). Glucose remained between 1.6 and 2.2 mM
from t = 60 to t = 120 min in both
groups. In saline-treated rats, insulin-induced hypoglycemia increased
plasma glucagon concentration from 262 ± 35 to a peak of
2,141 ± 348 pg/ml compared with an increase from 217 ± 18 to 2,070 ± 273 pg/ml in the amylin-treated rats (Fig.
4A). The area under the curve (AUC) for glucagon (2 h) was
not different between groups (saline: 2,115 ± 289 and amylin: 2,173 ± 302 pg · ml1 · h
1;
P = 0.91).
|
Effects of amylin on sequential arginine- and
hypoglycemia-stimulated glucagon secretion.
The glucagon response to the L-arginine challenge,
integrated over 90 min, was reduced by 45% in the amylin-infused rats
(559 ± 71 vs. 1,002 ± 162 pg · ml1 · h
1 in controls,
P < 0.05). Within 20 min of the variable glucose infusion being stopped, insulin reduced plasma glucose from 5.67 ± 0.03 to 2.44 ± 0.17 mM (amylin-treated rats) and from
5.67 ± 0.06 to 2.39 ± 0.17 mM (saline-treated rats), and
glucose remained between 1.6 and 2.2 mM over the next 100 min. In
response to this hypoglycemic challenge, plasma glucagon concentration
increased from 205 ± 43 to 2,544 ± 264 pg/ml in
amylin-treated rats and from 247 ± 49 to 2,761 ± 382 pg/ml
in control rats [glucagon AUC (120-240 min) 3,707 ± 507 vs.
4,401 ± 640 pg · ml
1 · h
1,
respectively; P = 0.44; Fig
5]; that is, in this animal model, amylin infusion significantly inhibited arginine-stimulated glucagon secretion, consistent with a previous description (7), but did not affect hypoglycemia-stimulated glucagon secretion.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In our isolated rat pancreas model, 1 mM rat amylin did not modify
glucagon release when perfused at low (3.2 mM), normal (5.5 mM), or
high (11 mM) glucose concentrations, and it failed to affect the
increase in glucagon output that followed the lowering of the perfusate
glucose concentration from 11 to 3.2 mM. In the isolated pancreas, 1 mM
amylin was also without effect on glucagon secreted in response to
established secretagogues such as arginine, VIP, and carbachol, in
agreement with previous results obtained with a 500-fold higher amylin
concentration (29). In a state of increased -cell
secretory activity (when the pancreas was perfused with 3.2 mM
glucose), the suppression of glucagon output induced by augmenting the
glucose concentration of the medium (to 7 mM) was not significantly
modified by the simultaneous infusion of amylin. In isolated islets,
100 nM amylin did not affect arginine-stimulated glucagon secretion.
That is, in neither isolated islets nor isolated pancreas preparations
was there an effect of amylin on glucagon secretion. These negative
findings in regard to glucagon secretion in isolated preparations
contrast with the clear inhibitory effect that amylin has on insulin
secretion in similar preparations (2, 3, 11, 20, 23, 26, 31,
33).
In the present study in anesthetized rats, the glucagon response to insulin-induced hypoglycemia was not affected by the infusion of amylin at pharmacological concentrations, but several studies now affirm an effect of physiological and/or therapeutic concentrations of amylin or analogs to inhibit nutrient-stimulated glucagon secretion in rodents and humans (1, 5-7, 18, 21). In an effort to reconcile this apparent dichotomy, arginine and hypoglycemia were used sequentially to stimulate glucagon secretion in the same animal in the present study. In this study, a glucagonostatic action observed after the arginine challenge phase was not present with even supraphysiological concentrations of amylin during hypoglycemic stimulation of glucagon secretion. This result newly identifies a selective glucagonostatic effect of amylin.
Our observations on the lack of effect of amylin on glucagon release from isolated islets disagree with the work of Wang et al. (32) but concur with other data presented here. It appears likely from the present set of experiments and from those reported from similar preparations that effects of amylin agonists to inhibit nutrient-stimulated glucagon secretion are not intrinsic to isolated islets or the isolated perfused pancreas; they are a feature of intact individuals. The present study does not identify what extrapancreatic mechanisms mediate this effect, but plausible explanations could include both humoral and neural pathways. This latter mechanism of action would be consistent with other glucose-dependent glucoregulatory effects of amylin that apparently reside in the area postrema (25) and are overridden by hypoglycemia (34). The autonomic nervous system appears to be implicated differently in hypoglycemia-stimulated than in arginine-stimulated glucagon secretion in normal women (10). It could prove that inhibition of glucagon secretion in response to each of these stimuli differentially involves autonomic mechanisms.
An amylin receptor agonist, pramlintide, is being explored for its utility in treatment of types of diabetic subjects in which exaggerated amino acid-stimulated glucagon secretion and excess glucagon action complicate metabolic control (8, 9, 17). The findings in the present study that this potentially antidiabetic action of amylin does not impede counterregulatory glucagon secretion could be relevant to clinical safety.
In conclusion, the present results demonstrate an effect of exogenous rat amylin to inhibit arginine-induced, but not hypoglycemia-induced, glucagon secretion in intact rats. The absence of any effect of rat amylin on glucagon release from isolated preparations indicates that its selective glucagonostatic effect is extrapancreatic and possibly centrally mediated. The finding that amylin does not modify the increase in glucagon secretion evoked by an abrupt decline in plasma glucose concentration suggests that therapeutic administration of amylin analogs would not suppress the counterregulatory glucagon response elicited by hypoglycemia.
![]() |
ACKNOWLEDGEMENTS |
---|
The expert technical assistance of Pilar García and Encarnación Gutiérrez is gratefully acknowledged. We thank Martha Messman for secretarial help.
![]() |
FOOTNOTES |
---|
This work was supported by grants from the Fondo de Investigación Sanitaria, Ministerio de Sanidad y Consumo (97/0933) and from the Comunidad Autónoma de Madrid (8.6/0005/98), Spain. J. Rodríguez-Gallardo was the recipient of a Research Fellowship from Q. F. Bayer (Spain).
Address for reprint requests and other correspondence: J. Marco, Clínica Puerta de Hierro, Universidad Autónoma de Madrid, San Martín de Porres, 4 28035 Madrid, Spain (E-mail: jmarco{at}hpth.insalud.es).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 26 June 2000; accepted in final form 31 October 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Beaumont, K,
Gedulin B,
Jodka C,
Lawler R,
and
Young A.
Concentration-response for glucagonostatic effect of pramlintide in rats (Abstract).
Diabetologia
41:
A168,
1998[ISI].
2.
Bennet, WM,
Beis CS,
Ghatei MA,
Byfield PGH,
and
Bloom SR.
Amylin tonally regulates arginine-stimulated insulin secretion in rats.
Diabetologia
37:
436-438,
1994[ISI][Medline].
3.
Dégano, P,
Silvestre RA,
Salas M,
Peiró E,
and
Marco J.
Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas.
Regul Pept
43:
91-96,
1993[ISI][Medline].
4.
Faloona, GR,
and
Unger R.
Glucagon.
In: Methods of Hormone Radioimmunoassay, edited by Jaffe BM,
and Behrman HR.. New York: Academic, 1974, p. 317-330.
5.
Gedulin, B,
Jodka C,
and
Young A.
Pramlintide inhibits arginine-induced glucagon secretion in rats (Abstract).
Diabet Med
14:
S26,
1997.
6.
Gedulin, B,
Percy A,
Jodka C,
and
Young A.
Endogenous amylin inhibits glucagon secretion, as demonstrated by studies using neutralizing antibody and the antagonist AC187 (Abstract).
Diabet Med
14:
S18,
1997.
7.
Gedulin, BR,
Rink TJ,
and
Young AA.
Dose-response for glucagonostatic effect of amylin in rats.
Metabolism
46:
67-70,
1997[ISI][Medline].
8.
Gerich, JE,
Lorenzi M,
Bier DM,
Schneider V,
Tsalikian E,
Karam JH,
and
Forsham PH.
Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.
N Engl J Med
292:
985-989,
1975[Abstract].
9.
Gerich, JE,
Tsalikian E,
Lorenzi M,
Schneider V,
Bohannon NV,
Gustafson G,
and
Karam JH.
Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin.
J Clin Endocrinol Metab
41:
1178-1180,
1975[Abstract].
10.
Havel, PJ,
and
Ahrén B.
Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women.
Diabetes
46:
801-807,
1997[Abstract].
11.
Kogire, M,
Ishizuka J,
Thompson JC,
and
Greeley GH.
Inhibitory action of islet amyloid polypeptide and calcitonin gene-related peptide on release of insulin from the isolated perfused rat pancreas.
Pancreas
6:
459-463,
1991[ISI][Medline].
12.
Kostianovsky, M,
Lacy PE,
Greider MH,
and
Still MF.
Long term (15 days) incubation of islets of Langerhans isolated from adult rats and mice.
Lab Invest
27:
53-61,
1972[ISI][Medline].
13.
Lakey, JR,
Warnock GL,
Ao Z,
and
Rajotte RV.
Bulk cryopreservation of isolated islets of Langerhans.
Cell Transplant
5:
395-404,
1996[ISI][Medline].
14.
Leclercq-Meyer, V,
Marchand J,
Leclercq R,
and
Malaisse WJ.
Glucagon and insulin release by the in vitro perfused rat pancreas.
Diabetes Metab
2:
57-65,
1976[ISI].
15.
Lehman-deGaeta, LS,
Willis AC,
Young AA,
Foot EA,
Albrecht E,
Leighton B,
Rink TJ,
and
Cooper GJS
Variability of chemically synthesized human amylin (Abstract).
Diabetes
40:
236A,
1991.
16.
Lindsey, CA,
Faloona GR,
and
Unger RH.
Plasma glucagon levels during rapid exsanguination with and without adrenergic blockade.
Diabetes
24:
313-316,
1975[Abstract].
17.
Müller, WA,
Faloona GR,
Aguilar-Parada E,
and
Unger RH.
Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.
N Engl J Med
283:
109-115,
1970[ISI][Medline].
18.
Nyholm, B,
Orskov L,
Hove KY,
Gravholt CH,
Moller N,
Alberti KG,
Moyses C,
Kolterman O,
and
Schmitz O.
The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Metabolism
48:
935-941,
1999[ISI][Medline].
19.
Ogawa, A,
Harris V,
McCorkle SK,
Unger RH,
and
Luskey KL.
Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment.
J Clin Invest
85:
973-976,
1990[ISI][Medline].
20.
Ohsawa, H,
Kanatsuka A,
Yamaguchi T,
Makino H,
and
Yoshida S.
Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets.
Biochem Biophys Res Commun
160:
961-967,
1989[ISI][Medline].
21.
Panagiotidis, G,
Salehi AA,
Westermark P,
and
Lundquist I.
Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse.
Diabetes Res Clin Pract
18:
167-171,
1992[ISI][Medline].
22.
Parkes, D,
Chen K,
Smith P,
and
Young A.
Amylin does not suppress hypoglycemia-induced secretion of glucagon in rats (Abstract).
Diabetes
48:
A425,
1999[ISI].
23.
Peiró, E,
Dégano P,
Silvestre RA,
and
Marco J.
Inhibition of insulin release by amylin is not mediated by changes in somatostatin output.
Life Sci
49:
761-765,
1991[ISI][Medline].
24.
Percy, AJ,
Trainor DA,
Rittenhouse J,
Phelps J,
and
Koda JE.
Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma.
Clin Chem
42:
576-585,
1996
25.
Riediger, T,
Rauch M,
Jurat G,
and
Schmid HA.
Central nervous targets for pancreatic amylin (Abstract).
Pflügers Arch Eur J Physiol Suppl
437:
R142,
1999.
26.
Salas, M,
Silvestre RA,
Garcia-Hermida O,
Fontela T,
Rodriguez-Gallardo J,
and
Marco J.
Inhibitory effect of amylin (islet amyloid polypeptide) on insulin response to non-glucose stimuli: study in perfused rat pancreas.
Diabetes Metab
21:
269-273,
1995[ISI].
27.
Siegel, S,
and
Castellan NJ.
Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill, 1988.
28.
Silvestre, RA,
Miralles P,
Moreno P,
Villanueva ML,
and
Marco J.
Somatostatin, insulin and glucagon secretion by the perfused pancreas from the cysteamine-treated rat.
Biochem Biophys Res Commun
134:
1291-1297,
1986[ISI][Medline].
29.
Silvestre, RA,
Peiró E,
Dégano P,
Miralles P,
and
Marco J.
Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas.
Regul Pept
31:
23-31,
1990[ISI][Medline].
30.
Silvestre, RA,
Rodríguez-Gallardo J,
Gutiérrez E,
García P,
Egido EM,
and
Marco J.
Failure of amylin to directly affect glucagon release. Study in the perfused rat pancreas (Abstract).
Diabetologia
42:
A146,
1999[ISI].
31.
Silvestre, RA,
Rodríguez-Gallardo J,
Gutiérrez E,
and
Marco J.
Influence of glucose concentration on the inhibitory effect of amylin on insulin secretion: study in the perfused rat pancreas.
Regul Pept
68:
31-35,
1997[ISI][Medline].
32.
Wang, F,
Adrian TE,
Westermark GT,
Ding XZ,
Gasslander T,
and
Permert J.
Islet amyloid polypeptide tonally inhibits -,
-, and
-cell secretion in isolated rat pancreatic islets.
Am J Physiol Endocrinol Metab
276:
E19-E24,
1999
33.
Wang, Z-L,
Bennet WM,
Ghatei MA,
Byfield PGH,
Smith DM,
and
Bloom SR.
Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets.
Diabetes
42:
330-335,
1993[Abstract].
34.
Young, A,
Moore C,
Herich J,
and
Beaumont K.
Neuroendocrine actions of amylin.
In: Calcitonin Gene-Related Peptide (CGRP), edited by Poyner D,
Marshall I,
and Brain S.. Austin, TX: Landes, 1999, chapt. 9, p. 91-102.
35.
Young, AA,
Rink TJ,
and
Wang MW.
Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP-alpha) in the fasted, anaesthetized rat.
Life Sci
52:
1717-1726,
1993[ISI][Medline].
36.
Young, AA,
Wang MW,
and
Cooper GJS
Amylin injection causes elevated plasma lactate and glucose in the rat.
FEBS Lett
291:
101-104,
1991[ISI][Medline].